Immune checkpoint blockade in cancer therapy Journal Article
| Authors: | Postow, M. A.; Callahan, M. K.; Wolchok, J. D. |
| Article Title: | Immune checkpoint blockade in cancer therapy |
| Abstract: | Immunologic checkpoint blockade with antibodies that target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD-L1) have demonstrated promise in a variety of malignancies. Ipilimumab (CTLA-4) and pembrolizumab (PD-1) are approved by the US Food and Drug Administration for the treatment of advanced melanoma, and additional regulatory approvals are expected across the oncologic spectrum for a variety of other agents that target these pathways. Treatment with both CTLA-4 and PD-1/PD-L1 blockade is associated with a unique pattern of adverse events called immune-related adverse events, and occasionally, unusual kinetics of tumor response are seen. Combination approaches involving CTLA-4 and PD-1/PD-L1 blockade are being investigated to determine whether they enhance the efficacy of either approach alone. Principles learned during the development of CTLA-4 and PD-1/PD-L1 approaches will likely be used as new immunologic checkpoint blocking antibodies begin clinical investigation. (C) 2015 by American Society of Clinical Oncology |
| Keywords: | phase-ii trial; metastatic melanoma; prostate-cancer; lymphocyte-associated antigen-4; ctla-4 blockade; cell lung-cancer; t-cells; adverse events; resistant; open-label; anti-ctla-4 antibody |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 17 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-06-10 |
| Start Page: | 1974 |
| End Page: | 1982 |
| Language: | English |
| ACCESSION: | WOS:000355999800019 |
| DOI: | 10.1200/jco.2014.59.4358 |
| PROVIDER: | wos |
| PUBMED: | 25605845 |
| PMCID: | PMC4980573 |
| Notes: | Review -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work